New inhaled migraine treatment shows promise in early trial
Knowledge-focused
Completed
This early-stage study tested a new inhaled powder form of the migraine drug dihydroergotamine (DHE) in 44 healthy adults. Researchers compared how the body absorbs the drug when inhaled versus when given as a nasal spray or injection. The goal was to check safety and measure dru…
Phase: PHASE1 • Sponsor: Aspeya Switzerland SA • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC